CCDC73 Inhibitors
CCDC73 inhibitors are a set of compounds that influence the activity of the coiled-coil domain-containing protein 73 through various biochemical and cellular mechanisms. Compounds like LY294002 and Wortmannin, which are PI3K inhibitors, could indirectly lead to the inhibition of CCDC73 by diminishing the phosphorylation and activation of downstream targets in the PI3K/AKT pathway. These targets are typically involved in processes such as cell growth and survival, which may be essential for the functioning of CCDC73. A reduction in PI3K/AKT signaling could, therefore, create a cellular milieu that is not conducive to CCDC73's role in cell division.
Similarly, inhibitors of the MEK/ERK pathway, such as PD0325901 and U0126, could decrease CCDC73 activity by preventing the necessary cell proliferation and growth signals from being relayed. Since CCDC73 is potentially involved in these processes, the suppression of MEK/ERK signaling may lead to a decrease in its functionality. Additionally, the proteasome inhibitor Bortezomib could lead to the stabilization of regulatory proteins that have the potential to interfere with CCDC73's activity. Furthermore, the stress response and cell differentiation pathways, which can be affected by inhibitors like SB203580 and SP600125, may also play a role in modulating the functional activity of CCDC73, suggesting that the inhibition of these pathways could indirectly decrease the activity of CCDC73.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a phosphoinositide 3-kinases (PI3K) inhibitor that impedes the PI3K/AKT signaling pathway. Inhibition of this pathway results in decreased phosphorylation and activation of downstream targets, including proteins involved in cell cycle progression. As CCDC73 is involved in cell division, the reduction of AKT activity can lead to the suppression of CCDC73 function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor that disrupts the mTORC1 signaling complex. This interruption leads to reduced protein synthesis and cell growth, which are crucial for the cellular processes in which CCDC73 is implicated. By mitigating mTOR activity, cellular conditions become less conducive for the functions typically facilitated by CCDC73. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a selective inhibitor of MAP kinase kinase (MEK), which acts upstream of extracellular signal-regulated kinases (ERK). By blocking MEK, the subsequent activation of ERK is prevented, which can decrease the activity of proteins that rely on the MEK/ERK pathway for their function or stability, including CCDC73. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAPK. Inhibition of p38 MAPK can hinder stress response pathways and cytokine production, which in turn can affect the stability and activity of proteins like CCDC73 that may be regulated by these signaling events. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which can block the JNK signaling pathway involved in apoptosis and cellular differentiation. This can lead to altered cellular states that are not favorable for CCDC73's role, effectively reducing its functional activity. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor that prevents the degradation of ubiquitinated proteins. This action can lead to the accumulation of regulatory proteins that may inhibit the function of CCDC73 through competitive or allosteric interactions. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin is a non-competitive inhibitor of the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA). By altering calcium homeostasis, it can disrupt signaling pathways that rely on calcium as a second messenger, potentially diminishing CCDC73 activity if CCDC73 is calcium-sensitive. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent and irreversible inhibitor of PI3K, leading to a decrease in AKT signaling. This reduction can lead to a decrease in cellular activities that require active PI3K/AKT signaling, thereby reducing the functionality of proteins like CCDC73 that are involved in those processes. | ||||||
NF449 | 627034-85-9 | sc-478179 sc-478179A sc-478179B | 10 mg 25 mg 100 mg | $203.00 $469.00 $1509.00 | 1 | |
NF449 is a potent and selective inhibitor of G-protein-coupled P2X purinoceptor 1. Disruption of purinergic signaling can alter various cellular processes, including those that may be necessary for CCDC73 activity, thereby indirectly leading to its inhibition. | ||||||
ZM 336372 | 208260-29-1 | sc-202857 | 1 mg | $47.00 | 2 | |
ZM336372 is a potent inhibitor of Raf-1 kinase, which can lead to reduced activation of the MAPK/ERK pathway. This decreased activity can affect proteins associated with this signaling cascade, potentially resulting in a reduction of CCDC73 activity. | ||||||